Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CANF 
Can Fite Biopharma Ltd ADR (CANF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CANF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.25
1 Year Target Price $7.25
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.06M USD | Price to earnings Ratio - | 1Y Target Price 7.25 |
Price to earnings Ratio - | 1Y Target Price 7.25 | ||
Volume (30-day avg) 2 | Beta 0.08 | 52 Weeks Range 0.63 - 3.12 | Updated Date 08/28/2025 |
52 Weeks Range 0.63 - 3.12 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1127.37% |
Management Effectiveness
Return on Assets (TTM) -53.18% | Return on Equity (TTM) -134.94% |
Valuation
Trailing PE - | Forward PE 2.97 | Enterprise Value 5260090 | Price to Sales(TTM) 19.38 |
Enterprise Value 5260090 | Price to Sales(TTM) 19.38 | ||
Enterprise Value to Revenue 7.8 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 14572900 | Shares Floating 2939231418 |
Shares Outstanding 14572900 | Shares Floating 2939231418 | ||
Percent Insiders - | Percent Institutions 5.89 |
Upturn AI SWOT
Can Fite Biopharma Ltd ADR
Company Overview
History and Background
Can-Fite BioPharma Ltd. was founded in 2000 and is an Israeli biopharmaceutical company focused on developing and commercializing novel therapeutics for inflammatory, liver, and metabolic diseases. It is listed on the New York Stock Exchange (NYSE American) under the symbol CANF. Their focus is on small molecule, orally bioavailable compounds with a good safety profile.
Core Business Areas
- Liver Diseases: Development of Piclidenoson and Namodenoson for the treatment of liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma (HCC).
- Inflammatory Diseases: Development of Piclidenoson for the treatment of inflammatory diseases such as psoriasis and rheumatoid arthritis.
- Metabolic Diseases: Research and development efforts also target metabolic diseases.
Leadership and Structure
Can-Fite BioPharma is led by a management team with experience in drug development and commercialization. The company has a board of directors that provides oversight and guidance.
Top Products and Market Share
Key Offerings
- Piclidenoson: A small molecule drug in Phase III clinical trials for psoriasis and rheumatoid arthritis. Also being explored for other inflammatory conditions. Market share data not publicly available. Competitors include companies with biologics and other small molecule inhibitors, such as Amgen (Enbrel), AbbVie (Humira, Rinvoq), and Bristol Myers Squibb (Otezla).
- Namodenoson: A small molecule drug in Phase II clinical trials for Hepatocellular Carcinoma (HCC) and NASH. Market share data not publicly available as it is still in development. Competitors in HCC include companies with checkpoint inhibitors and tyrosine kinase inhibitors, such as Roche (Tecentriq, Avastin) and Bayer (Nexavar).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and competition. The market for liver diseases, inflammatory diseases, and metabolic diseases is substantial and growing, driven by factors such as aging populations, lifestyle changes, and increasing prevalence of chronic conditions.
Positioning
Can-Fite BioPharma is positioned as a company focused on developing oral, small molecule therapeutics with a good safety profile for unmet medical needs. Their competitive advantage lies in their unique drug candidates and their potential to address large and growing markets.
Total Addressable Market (TAM)
The total addressable market for psoriasis, rheumatoid arthritis, NAFLD/NASH, and HCC is estimated to be billions of dollars. Can-Fite is positioned to capture a portion of this market with successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Oral administration route
- Good safety profile (preliminary data)
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Lack of commercialized products
- Small market capitalization
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Regulatory approvals
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory delays
- Funding challenges
Competitors and Market Share
Key Competitors
- AMGN
- ABBV
- BMY
- ROCHE
- BAYRY
Competitive Landscape
Can-Fite Biopharma faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Their success depends on differentiating their products through efficacy, safety, and oral administration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial progress and licensing agreements, resulting in inconsistent revenue.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates vary depending on the success of their pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for Piclidenoson and Namodenoson, as well as seeking partnerships for commercialization.
Summary
Can-Fite Biopharma is a biopharmaceutical company focused on developing novel therapeutics for inflammatory and liver diseases. The company's success hinges on the positive results of its clinical trials, especially for Piclidenoson and Namodenoson. Their weak financial standing and small size, however, leave them vulnerable. Overcoming its weaknesses and capitalizing on successful drug development should be a priority for Can-Fite Biopharma Ltd ADR.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Can Fite Biopharma Ltd ADR
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2012-11-06 | CEO and Chief Financial & Operating Officer Mr. Motti Farbstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.canfite.com |
Full time employees 5 | Website https://www.canfite.com | ||
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.